Inna V. Smagina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Inna V. Smagina has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Аleksey N. Boyko
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
8 shared publications - E. Yu. Elchaninova
Altai State Medical University
6 shared publications - Stella A. Sivertseva
Medical and sanitary unit «Neftyanik
6 shared publications - Zoya Alexandrovna Goncharova
Rostov State Medical University, Ministry of Health of Russia
6 shared publications - A. I. Afanas’eVa
Altai State Medical University
5 shared publications - Farit A. Khabirov
Kazan State Medical Academy – a branch of the Russian Medical Academy of Continuing Professional Education
5 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 117-121
Sleep disorders in myasthenia gravis: clinical, pathophysiological and therapeutic aspects
Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, the clinical burden of which is not limited to fluctuating muscle weakness. Data on the prevalence of sleep disorders in patients with MG vary considerably, which is due to the heterogeneity of clinical approaches and the limited use of objective methods for assessing sleep. At the same time, a number of studies point to specific patterns of sleep disorders in this patient group. For example, in one study, obstructive sleep apnea was detected in 36% of patients with MG, compared with the expected 15–20% in the general population. Restless legs syndrome was also detected more than twice as frequently: in 43.2% of patients with MG and in 20% of the control group. According to a recent systematic review, the prevalence of excessive daytime sleepiness reached 75% in some studies. The impact of treatment deserves special attention: among patients with generalized myasthenia gravis who had been receiving oral glucocorticoids (GCs) for at least one year, insomnia was observed in 23.1%. The development of sleep disorders in MG is likely to be multifactorial. Sleep-related breathing disorders may be associated with weakness of the respiratory muscles and an increased risk of nocturnal hypoventilation and episodes of desaturation, particularly during the rapid eye movement (REM) phase. Difficulties in falling asleep and maintaining sleep may arise against a background of fatigue, anxiety and depressive disorders, and treatment, primarily with GCs. The role of immuno-inflammatory mechanisms is of interest but requires further investigation. The aim of this review is to summarize current evidence on the clinical manifestations, possible mechanisms, diagnosis and management of sleep disorders in myasthenia gravis. Particular attention is paid to insomnia, sleep-related breathing disorders, restless legs syndrome, the impact of treatment and the need for active screening for sleep disorders in clinical practice.
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 117-121
Open AccessSleep disorders in myasthenia gravis: clinical, pathophysiological and therapeutic aspects
Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, the clinical burden of which is not limited to fluctuating muscle weakness. Data on the prevalence of sleep disorders in patients with MG vary considerably, which is due to the heterogeneity of clinical approaches and the limited use of objective methods for assessing sleep. At the same time, a number of studies point to specific patterns of sleep disorders in this patient group. For example, in one study, obstructive sleep apnea was detected in 36% of patients with MG, compared with the expected 15–20% in the general population. Restless legs syndrome was also detected more than twice as frequently: in 43.2% of patients with MG and in 20% of the control group. According to a recent systematic review, the prevalence of excessive daytime sleepiness reached 75% in some studies. The impact of treatment deserves special attention: among patients with generalized myasthenia gravis who had been receiving oral glucocorticoids (GCs) for at least one year, insomnia was observed in 23.1%. The development of sleep disorders in MG is likely to be multifactorial. Sleep-related breathing disorders may be associated with weakness of the respiratory muscles and an increased risk of nocturnal hypoventilation and episodes of desaturation, particularly during the rapid eye movement (REM) phase. Difficulties in falling asleep and maintaining sleep may arise against a background of fatigue, anxiety and depressive disorders, and treatment, primarily with GCs. The role of immuno-inflammatory mechanisms is of interest but requires further investigation. The aim of this review is to summarize current evidence on the clinical manifestations, possible mechanisms, diagnosis and management of sleep disorders in myasthenia gravis. Particular attention is paid to insomnia, sleep-related breathing disorders, restless legs syndrome, the impact of treatment and the need for active screening for sleep disorders in clinical practice.
- Open Access
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Open AccessDivozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- 10 June 2025
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 30 (2) , 27-31
Neurofilament light chain in blood and features of the multiple sclerosis course in patients with a history of traumatic brain injury
Multiple sclerosis (MS) is a chronic disease of the central nervous system with recurrent exacerbations, leading to irreversible disability, the development of which is based on axonal damage and demyelination. It is assumed that one of the candidate biomarkers of axonal damage may be a peptide component of the neuronal cytoskeleton — neurofilament light chain (NFL). Traumatic brain injury (TBI) before the onset of MS is associated with an increased rate of progression of neurological which may be due to increased astrogliosis as a late consequence of TBI. Objective: to evaluate the relationship between the level of NFL in the blood and the RP and exacerbation frequency MS in the presence/absence of TBI before the onset of MS.Material and methods. Caucasians born and living in the Altai region of Russia with relapsing-remitting MS in remission took part in a cross-sectional observational randomized study: 43 patients without a history of TBI and 43 patients with TBI before the onset of MS (MS duration 7.6 ± 6.6 and 5.9 ± 4.6 years, respectively, p = 0,113). Intracranial injury occurred 14.8 ± 7.8 years before the onset of MS and was documented as a concussion in 76% of patients.Results. The patient groups did not differ in the frequency of MS exacerbations, while RP was higher in the group with a history of TBI (p = 0.013). There were no intergroup differences in NFL levels (p = 0.613), as well as no correlations between NFL levels and RP (p = 0.499 and p = 0.776 groups with/without TBI, respectively) and the exacerbation frequency. No differences were found between subgroups of patients with different clinical forms of TBI in RP and NFL levels (H = 5,07; p = 0,679).Conclusion. The results of the study indicate a low probability of a connection between the level of NFL in the blood of patients with MS during the period of remission, both with the possible long-term consequences of a TBI received before the onset of MS, and with the course of MS.
- 10 June 2025
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 30 (2) , 27-31
Neurofilament light chain in blood and features of the multiple sclerosis course in patients with a history of traumatic brain injury
Multiple sclerosis (MS) is a chronic disease of the central nervous system with recurrent exacerbations, leading to irreversible disability, the development of which is based on axonal damage and demyelination. It is assumed that one of the candidate biomarkers of axonal damage may be a peptide component of the neuronal cytoskeleton — neurofilament light chain (NFL). Traumatic brain injury (TBI) before the onset of MS is associated with an increased rate of progression of neurological which may be due to increased astrogliosis as a late consequence of TBI. Objective: to evaluate the relationship between the level of NFL in the blood and the RP and exacerbation frequency MS in the presence/absence of TBI before the onset of MS.Material and methods. Caucasians born and living in the Altai region of Russia with relapsing-remitting MS in remission took part in a cross-sectional observational randomized study: 43 patients without a history of TBI and 43 patients with TBI before the onset of MS (MS duration 7.6 ± 6.6 and 5.9 ± 4.6 years, respectively, p = 0,113). Intracranial injury occurred 14.8 ± 7.8 years before the onset of MS and was documented as a concussion in 76% of patients.Results. The patient groups did not differ in the frequency of MS exacerbations, while RP was higher in the group with a history of TBI (p = 0.013). There were no intergroup differences in NFL levels (p = 0.613), as well as no correlations between NFL levels and RP (p = 0.499 and p = 0.776 groups with/without TBI, respectively) and the exacerbation frequency. No differences were found between subgroups of patients with different clinical forms of TBI in RP and NFL levels (H = 5,07; p = 0,679).Conclusion. The results of the study indicate a low probability of a connection between the level of NFL in the blood of patients with MS during the period of remission, both with the possible long-term consequences of a TBI received before the onset of MS, and with the course of MS.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 198-202
Clinical and epidemiological characteristics of myasthenia in the Altai region
Objective. To analyze the epidemiological and clinical characteristics of myasthenia gravis (MG) in the Altai region (AR). Material and methods. One hundred and twenty-two patients with a verified diagnosis of MG, living in the AR, took part in the study. To collect data, a questionnaire was developed, the data of which formed the basis for the study. Data analysis was carried out using the Statistica 12 program (Stat. Soft, Inc.). Results. The group of patients studied makes up 14—28% of the expected number of patients with MG in AR. In general, patients with late onset of the disease predominated in the group (71 people versus 51). A predominance of women was revealed in the group with an early onset of the disease, while in the group with a late onset the ratio of men and women levels out. The identification of two peaks in the age of onset of the disease in women, which was not observed in the group of men, was a feature of the clinical course of MG in AR. In the study group, the generalized form of MG was more common; the onset of the disease in most patients began with weakness of the external eye muscles. In most patients, MG was associated with antibodies to the acetylcholine receptor, but seronegative cases were also noted. A rarer frequency of thymus pathology has been established. An analysis was carried out of the factors that preceded the onset of MG, among which the most common was viral infection. Conclusion. The clinical and epidemiological features of MG in AR are described. Further monitoring of clinical and epidemiological data on MG in AR will make it possible to clarify the regional characteristics of risk factors for the development and course of the disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 198-202
Clinical and epidemiological characteristics of myasthenia in the Altai region
Objective. To analyze the epidemiological and clinical characteristics of myasthenia gravis (MG) in the Altai region (AR). Material and methods. One hundred and twenty-two patients with a verified diagnosis of MG, living in the AR, took part in the study. To collect data, a questionnaire was developed, the data of which formed the basis for the study. Data analysis was carried out using the Statistica 12 program (Stat. Soft, Inc.). Results. The group of patients studied makes up 14—28% of the expected number of patients with MG in AR. In general, patients with late onset of the disease predominated in the group (71 people versus 51). A predominance of women was revealed in the group with an early onset of the disease, while in the group with a late onset the ratio of men and women levels out. The identification of two peaks in the age of onset of the disease in women, which was not observed in the group of men, was a feature of the clinical course of MG in AR. In the study group, the generalized form of MG was more common; the onset of the disease in most patients began with weakness of the external eye muscles. In most patients, MG was associated with antibodies to the acetylcholine receptor, but seronegative cases were also noted. A rarer frequency of thymus pathology has been established. An analysis was carried out of the factors that preceded the onset of MG, among which the most common was viral infection. Conclusion. The clinical and epidemiological features of MG in AR are described. Further monitoring of clinical and epidemiological data on MG in AR will make it possible to clarify the regional characteristics of risk factors for the development and course of the disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (10) , 80-84
Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis?
Objective To evaluate the relationship between the level of glial fibrillary acidic protein (GFAP) in the blood and the rate of progression (RP) of neurological disorders and exacerbation frequency of multiple sclerosis (MS) in the presence/absence of traumatic brain injury (TBI) before the onset of MS. Material and methods. Caucasians born and living in the Altai region of Russia with relapsing-remitting MS in remission took part in a cross-sectional observational randomized study: 43 patients without a history of TBI and 43 patients with TBI before the onset of MS (mean age 36.1±9.3 and 33.5±8.2 years, MS duration 7.6±6.6 and 5.9±4.6 years, respectively). Intracranial injury occurred 14.8±7.8 years before the onset of MS and was documented as a concussion in 76% of patients. Results. The patient groups did not differ in the frequency of MS exacerbations, while RP was higher in the group with a history of TBI (p=0.013). There were no intergroup differences in GFAP levels, as well as no correlations between GFAP levels and RP (p=0.520 and p=0.255 in groups with/without TBI, respectively) and the exacerbation frequency. No differences were found between subgroups of patients with different clinical forms of TBI in RP and GFAP levels (H=0.26; p=0.880 and H=1.48; p=0.476, respectively). There was no correlation of the TBI duration with RP (p=0.902) and GFAP level (p=0.413). Conclusion. The results indicate a low probability of a connection between the level of GFAP in the blood of patients with MS during the period of remission, both with the possible long-term consequences of a TBI occurred before the onset of MS, and during the course of MS.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (10) , 80-84
Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis?
Objective To evaluate the relationship between the level of glial fibrillary acidic protein (GFAP) in the blood and the rate of progression (RP) of neurological disorders and exacerbation frequency of multiple sclerosis (MS) in the presence/absence of traumatic brain injury (TBI) before the onset of MS. Material and methods. Caucasians born and living in the Altai region of Russia with relapsing-remitting MS in remission took part in a cross-sectional observational randomized study: 43 patients without a history of TBI and 43 patients with TBI before the onset of MS (mean age 36.1±9.3 and 33.5±8.2 years, MS duration 7.6±6.6 and 5.9±4.6 years, respectively). Intracranial injury occurred 14.8±7.8 years before the onset of MS and was documented as a concussion in 76% of patients. Results. The patient groups did not differ in the frequency of MS exacerbations, while RP was higher in the group with a history of TBI (p=0.013). There were no intergroup differences in GFAP levels, as well as no correlations between GFAP levels and RP (p=0.520 and p=0.255 in groups with/without TBI, respectively) and the exacerbation frequency. No differences were found between subgroups of patients with different clinical forms of TBI in RP and GFAP levels (H=0.26; p=0.880 and H=1.48; p=0.476, respectively). There was no correlation of the TBI duration with RP (p=0.902) and GFAP level (p=0.413). Conclusion. The results indicate a low probability of a connection between the level of GFAP in the blood of patients with MS during the period of remission, both with the possible long-term consequences of a TBI occurred before the onset of MS, and during the course of MS.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (4) , 86-96
Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
OBJECTIVE To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks during 100 weeks for the treatment of patients with multiple sclerosis (MS), including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses. MATERIAL AND METHODS The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS (NCT05385744) included 338 adult patients with MS distributed in a 1:1 ratio into two groups: DIV 500 mg and teriflunomide (TRF) 14 mg. After screening, subjects were included in the main CT period, which consisted of two cycles of therapy over 48 weeks, then entered an additional period from weeks 49 to 100, which included three cycles of therapy. The efficacy was assessed based on the results of brain MRI and registration of data on relapses. RESULTS 308 subjects completed 5 therapy cycles according to the study protocol. An analysis of the effectiveness of DIV therapy over 2 years showed a persistent suppression of MRI and clinical activity of the disease in comparison with TRF, which was confirmed by all the studied MRI indicators (including CUA; total number of gadolinium-enhancing (GdE) lesions on T1-weighted scans ; number of new or enlarged lesions on T2-weighted scans; lesions volume change on T2-weighted scans; change in the volume of hypointense lesions on T1-weighted scans). The use of DIV was associated with a statistically significant decrease in ARR compared to TRF (p=0.0001). The ARR in the DIV group was 0.057, in the TRF group — 0.164 with 95% confidential interval for the frequency ratio [0.202; 0.593]. The incidence of GdE lesions on T1-weighted scans in the DIV group was significantly lower than in the TRF group. The average number of such lesions was 0.0±0.08 and 1.0±4.46 in the DIV and TRF groups, respectively (pp=0.0075). The proportion of patients with relapses was 11.2% (n=19) in the DIV group and 23.1% (n=39) in the TRF group (p=0.0039). In the subpopulation of patients with SPMS, no cases of increase in EDSS were detected, and not a single case of exacerbation was recorded over 2 years of using DIV. Also, DIV has shown a favorable safety profile. Among the adverse reactions (AR), infusion reactions and laboratory abnormalities, such as a decrease in the number of leukocytes, neutrophils, and lymphocytes, were most often recorded. Identified AR were expected, had mild to moderate severity, and resolved without any negative consequences. CONCLUSION The results of the BCD-132-4/MIRANTIBUS CT indicate a high sustained efficacy and safety of long-term use of DIV in comparison with TRF during 2 years of therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (4) , 86-96
Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
OBJECTIVE To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks during 100 weeks for the treatment of patients with multiple sclerosis (MS), including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses. MATERIAL AND METHODS The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS (NCT05385744) included 338 adult patients with MS distributed in a 1:1 ratio into two groups: DIV 500 mg and teriflunomide (TRF) 14 mg. After screening, subjects were included in the main CT period, which consisted of two cycles of therapy over 48 weeks, then entered an additional period from weeks 49 to 100, which included three cycles of therapy. The efficacy was assessed based on the results of brain MRI and registration of data on relapses. RESULTS 308 subjects completed 5 therapy cycles according to the study protocol. An analysis of the effectiveness of DIV therapy over 2 years showed a persistent suppression of MRI and clinical activity of the disease in comparison with TRF, which was confirmed by all the studied MRI indicators (including CUA; total number of gadolinium-enhancing (GdE) lesions on T1-weighted scans ; number of new or enlarged lesions on T2-weighted scans; lesions volume change on T2-weighted scans; change in the volume of hypointense lesions on T1-weighted scans). The use of DIV was associated with a statistically significant decrease in ARR compared to TRF (p=0.0001). The ARR in the DIV group was 0.057, in the TRF group — 0.164 with 95% confidential interval for the frequency ratio [0.202; 0.593]. The incidence of GdE lesions on T1-weighted scans in the DIV group was significantly lower than in the TRF group. The average number of such lesions was 0.0±0.08 and 1.0±4.46 in the DIV and TRF groups, respectively (pp=0.0075). The proportion of patients with relapses was 11.2% (n=19) in the DIV group and 23.1% (n=39) in the TRF group (p=0.0039). In the subpopulation of patients with SPMS, no cases of increase in EDSS were detected, and not a single case of exacerbation was recorded over 2 years of using DIV. Also, DIV has shown a favorable safety profile. Among the adverse reactions (AR), infusion reactions and laboratory abnormalities, such as a decrease in the number of leukocytes, neutrophils, and lymphocytes, were most often recorded. Identified AR were expected, had mild to moderate severity, and resolved without any negative consequences. CONCLUSION The results of the BCD-132-4/MIRANTIBUS CT indicate a high sustained efficacy and safety of long-term use of DIV in comparison with TRF during 2 years of therapy.
- Open Access
- 17 December 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (6) , 146-150
Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting
A joint conclusion of the Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” on the organization of medical care, diagnosis and treatment of multiple sclerosis (MS) and other autoimmune diseases is presented. 12 neurologists from different medical institutions in Russia and Belarus took part in the work of the Council. In the conclusions of the Council, special attention was paid to two new Russian original drugs, modifying the course of MS. The place of these drugs in the healthcare system of these countries was determined. Sampeginterferon beta-1a itself is an effective and safe drug of first choice (first-line treatment) for relapsing remitting MS. Divozilimab is a highly effective and safe second-line treatment indicated for rapidly progressive and highly active MS, even when substituted for a firstor second-line treatment in relapsing remitting and secondary progressive (with exacerbations) MS. The experts emphasized how promising the use of these drugs is in the complex treatment of MS.
- 17 December 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (6) , 146-150
Open AccessRussian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting
A joint conclusion of the Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” on the organization of medical care, diagnosis and treatment of multiple sclerosis (MS) and other autoimmune diseases is presented. 12 neurologists from different medical institutions in Russia and Belarus took part in the work of the Council. In the conclusions of the Council, special attention was paid to two new Russian original drugs, modifying the course of MS. The place of these drugs in the healthcare system of these countries was determined. Sampeginterferon beta-1a itself is an effective and safe drug of first choice (first-line treatment) for relapsing remitting MS. Divozilimab is a highly effective and safe second-line treatment indicated for rapidly progressive and highly active MS, even when substituted for a firstor second-line treatment in relapsing remitting and secondary progressive (with exacerbations) MS. The experts emphasized how promising the use of these drugs is in the complex treatment of MS.
- 5 October 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (9) , 76-82
Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить степень тяжести и частоту возникновения инфузионных реакций (ИР) на фоне терапии препаратом алемтузумаб у пациентов с высокоактивным течением рассеянного склероза (ВАРС) в российской популяции. МАТЕРИАЛ И МЕТОДЫ В данном ретроспективном исследовании были проанализированы данные 50 пациентов с ВАРС из 6 региональных центров РС России, получивших по два курса алемтузумаба в период с 2018 по 2022 г. РЕЗУЛЬТАТЫ Из всех ИР чаще всего отмечалось появление высыпаний по типу крапивницы (n=27), преимущественно легкой степени тяжести (70,6%). На втором месте по частоте возникновения оказалась головная боль (n=17, 34%). При сравнении группы пациентов, которым проводилась музыкотерапия (МТ), и тех, кто получал алемтузумаб без МТ, статистически значимой разницы частоты и тяжести ИР не было. ЗАКЛЮЧЕНИЕ У всех пациентов были зарегистрированы ИР разной степени выраженности. Отмечалось уменьшение балла по шкале инвалидизации EDSS. МТ не оказала влияния на возникновение ИР и степень их выраженности.
- 5 October 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (9) , 76-82
Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить степень тяжести и частоту возникновения инфузионных реакций (ИР) на фоне терапии препаратом алемтузумаб у пациентов с высокоактивным течением рассеянного склероза (ВАРС) в российской популяции. МАТЕРИАЛ И МЕТОДЫ В данном ретроспективном исследовании были проанализированы данные 50 пациентов с ВАРС из 6 региональных центров РС России, получивших по два курса алемтузумаба в период с 2018 по 2022 г. РЕЗУЛЬТАТЫ Из всех ИР чаще всего отмечалось появление высыпаний по типу крапивницы (n=27), преимущественно легкой степени тяжести (70,6%). На втором месте по частоте возникновения оказалась головная боль (n=17, 34%). При сравнении группы пациентов, которым проводилась музыкотерапия (МТ), и тех, кто получал алемтузумаб без МТ, статистически значимой разницы частоты и тяжести ИР не было. ЗАКЛЮЧЕНИЕ У всех пациентов были зарегистрированы ИР разной степени выраженности. Отмечалось уменьшение балла по шкале инвалидизации EDSS. МТ не оказала влияния на возникновение ИР и степень их выраженности.
- 10 August 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (7) , 43-52
Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
ЦЕЛЬ ИССЛЕДОВАНИЯ Сравнение эффективности и безопасности курса дивозилимаба (ДИВ) по сравнению с терифлуномидом (ТРФ) при рассеянном склерозе (РС) с обострениями (РСО), включавшим ремиттирующий РС и вторично-прогрессирующий РС с обострениями. МАТЕРИАЛ И МЕТОДЫ Проведено многоцентровое рандомизированное двойное слепое и двойное маскированное клиническое исследование (КИ) 3 фазы BCD-132-4/MIRANTIBUS, включавшее 338 взрослых пациентов с РСО, распределенных в соотношении 1:1 в две группы: ДИВ и ТРФ. После скринингового обследования пациенты включались в основной период КИ, состоявший из двух циклов терапии в течение 48 нед. Первичной конечной точкой КИ являлась среднегодовая частота обострений через 48 нед после рандомизации последнего пациента в исследование. РЕЗУЛЬТАТЫ В соответствии с протоколом исследования 321 пациент завершил 48 нед терапию. Проведенный анализ данных эффективности по первичной конечной точке позволил доказать гипотезу превосходства исследуемого препарата ДИВ относительно ТРФ. Быстрое подавление острой активности по результатам МРТ головного мозга и клинических проявлений заболевания зарегистрировано уже после первой инфузии ДИВ у пациентов с РСО. Так, через 48 нед терапии у пациентов группы ДИВ отсутствовали очаги, накапливающие контраст в T1-режиме, при этом в группе ТРФ такие очаги отмечались у 20,7% (35/169) субъектов. Оценка показателя CUA per scan продемонстрировала, что средние значения за оцениваемый период были статистически значимо ниже в группе ДИВ по сравнению с группой ТРФ: отношение скорректированных частот per scan (ДИВ/ТРФ) составило 0,125 [95% ДИ 0,089; 0,177]. За 48 нед терапии доля пациентов с обострениями составила 9,5% (16/169) в группе ДИВ и 19,5% (33/169) — в группе ТРФ (p=0,0086). Из нежелательных реакций (НР) наиболее часто регистрировались инфузионные реакции и отклонения лабораторных данных, таких как снижение числа лейкоцитов, нейтрофилов, лимфоцитов. Выявленные НР были ожидаемыми, имели легкую и умеренную степень тяжести и разрешились без негативных последствий. ЗАКЛЮЧЕНИЕ Результаты клинического исследования указывают на высокую эффективность и безопасность ДИВ в сравнении с ТРФ.
- 10 August 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (7) , 43-52
Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
ЦЕЛЬ ИССЛЕДОВАНИЯ Сравнение эффективности и безопасности курса дивозилимаба (ДИВ) по сравнению с терифлуномидом (ТРФ) при рассеянном склерозе (РС) с обострениями (РСО), включавшим ремиттирующий РС и вторично-прогрессирующий РС с обострениями. МАТЕРИАЛ И МЕТОДЫ Проведено многоцентровое рандомизированное двойное слепое и двойное маскированное клиническое исследование (КИ) 3 фазы BCD-132-4/MIRANTIBUS, включавшее 338 взрослых пациентов с РСО, распределенных в соотношении 1:1 в две группы: ДИВ и ТРФ. После скринингового обследования пациенты включались в основной период КИ, состоявший из двух циклов терапии в течение 48 нед. Первичной конечной точкой КИ являлась среднегодовая частота обострений через 48 нед после рандомизации последнего пациента в исследование. РЕЗУЛЬТАТЫ В соответствии с протоколом исследования 321 пациент завершил 48 нед терапию. Проведенный анализ данных эффективности по первичной конечной точке позволил доказать гипотезу превосходства исследуемого препарата ДИВ относительно ТРФ. Быстрое подавление острой активности по результатам МРТ головного мозга и клинических проявлений заболевания зарегистрировано уже после первой инфузии ДИВ у пациентов с РСО. Так, через 48 нед терапии у пациентов группы ДИВ отсутствовали очаги, накапливающие контраст в T1-режиме, при этом в группе ТРФ такие очаги отмечались у 20,7% (35/169) субъектов. Оценка показателя CUA per scan продемонстрировала, что средние значения за оцениваемый период были статистически значимо ниже в группе ДИВ по сравнению с группой ТРФ: отношение скорректированных частот per scan (ДИВ/ТРФ) составило 0,125 [95% ДИ 0,089; 0,177]. За 48 нед терапии доля пациентов с обострениями составила 9,5% (16/169) в группе ДИВ и 19,5% (33/169) — в группе ТРФ (p=0,0086). Из нежелательных реакций (НР) наиболее часто регистрировались инфузионные реакции и отклонения лабораторных данных, таких как снижение числа лейкоцитов, нейтрофилов, лимфоцитов. Выявленные НР были ожидаемыми, имели легкую и умеренную степень тяжести и разрешились без негативных последствий. ЗАКЛЮЧЕНИЕ Результаты клинического исследования указывают на высокую эффективность и безопасность ДИВ в сравнении с ТРФ.
- 10 August 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (7) , 72-76
Traumatic brain injury before the multiple sclerosis onset: a relationship with the progression of neurological disorders and pathobiochemical markers of the cerebrospinal fluid
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить связь черепно-мозговой травмы (ЧМТ), полученной до дебюта рассеянного склероза (РС), со скоростью прогрессирования неврологических расстройств и маркерами проницаемости гематоэнцефалического барьера, воспаления, демиелинизации и глиоза в цереброспинальной жидкости. МАТЕРИАЛ И МЕТОДЫ В проспективном контролируемом рандомизированном исследовании приняли участие 88 больных ремиттирующим РС Алтайского края России с/без ЧМТ до дебюта РС (n=44; 19 мужчин, 25 женщин в каждой группе). Нарастание инвалидизации оценивали ретроспективно. Плеоцитоз, уровень белка, альбумина, С-реактивного белка, TNF-α, основного белка миелина, белка S100 измеряли в цереброспинальной жидкости в подгруппах пациентов (n=14 в каждой из групп) в периоды ремиссии и обострения РС. РЕЗУЛЬТАТЫ В группе больных с ЧМТ до дебюта РС документированы сотрясение и ушиб головного мозга легкой степени у 35 (79,5%) и 9 (20,5%) пациентов соответственно. У 72,5% больных ЧМТ была в возрасте старше 15 лет. Скорость прогрессирования PC была выше в группе больных с ЧМТ по сравнению с группой больных без ЧМТ (0,76±1,28 и 0,40±0,43 балла EDSS в год соответственно; p=0,014). ЧМТ до дебюта РС повышает риск нарастания инвалидизации более чем на 0,25 балла EDSS в год (ОШ 2,74; 95% ДИ 1,10—6,85; p=0,029). Ни при обострении, ни в период ремиссии РС не найдено межгрупповых различий исследованных показателей цереброспинальной жидкости. ЗАКЛЮЧЕНИЕ Сотрясение или ушиб головного мозга легкой степени тяжести до развития РС могут быть факторами, влияющими на прогрессирование неврологического дефицита. Представляется актуальным исследование механизмов неблагоприятного влияния ЧМТ на прогрессирование РС.
- 10 August 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (7) , 72-76
Traumatic brain injury before the multiple sclerosis onset: a relationship with the progression of neurological disorders and pathobiochemical markers of the cerebrospinal fluid
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить связь черепно-мозговой травмы (ЧМТ), полученной до дебюта рассеянного склероза (РС), со скоростью прогрессирования неврологических расстройств и маркерами проницаемости гематоэнцефалического барьера, воспаления, демиелинизации и глиоза в цереброспинальной жидкости. МАТЕРИАЛ И МЕТОДЫ В проспективном контролируемом рандомизированном исследовании приняли участие 88 больных ремиттирующим РС Алтайского края России с/без ЧМТ до дебюта РС (n=44; 19 мужчин, 25 женщин в каждой группе). Нарастание инвалидизации оценивали ретроспективно. Плеоцитоз, уровень белка, альбумина, С-реактивного белка, TNF-α, основного белка миелина, белка S100 измеряли в цереброспинальной жидкости в подгруппах пациентов (n=14 в каждой из групп) в периоды ремиссии и обострения РС. РЕЗУЛЬТАТЫ В группе больных с ЧМТ до дебюта РС документированы сотрясение и ушиб головного мозга легкой степени у 35 (79,5%) и 9 (20,5%) пациентов соответственно. У 72,5% больных ЧМТ была в возрасте старше 15 лет. Скорость прогрессирования PC была выше в группе больных с ЧМТ по сравнению с группой больных без ЧМТ (0,76±1,28 и 0,40±0,43 балла EDSS в год соответственно; p=0,014). ЧМТ до дебюта РС повышает риск нарастания инвалидизации более чем на 0,25 балла EDSS в год (ОШ 2,74; 95% ДИ 1,10—6,85; p=0,029). Ни при обострении, ни в период ремиссии РС не найдено межгрупповых различий исследованных показателей цереброспинальной жидкости. ЗАКЛЮЧЕНИЕ Сотрясение или ушиб головного мозга легкой степени тяжести до развития РС могут быть факторами, влияющими на прогрессирование неврологического дефицита. Представляется актуальным исследование механизмов неблагоприятного влияния ЧМТ на прогрессирование РС.